NewEdge Wealth LLC Has $940,000 Holdings in argenex SE $ARGX

NewEdge Wealth LLC grew its holdings in argenex SE (NASDAQ:ARGX) by 269.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,118 shares of the company’s stock after purchasing an additional 815 shares during the period. NewEdge Wealth LLC’s holdings in argenex were worth $940,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in ARGX. Abound Wealth Management boosted its holdings in shares of argenex by 3,200.0% during the fourth quarter. Abound Wealth Management now owns 33 shares of the company’s stock worth $28,000 after purchasing an additional 32 shares during the period. Sound Income Strategies LLC acquired a new position in argenex in the 4th quarter valued at approximately $28,000. Ameriflex Group Inc. purchased a new stake in argenex in the 3rd quarter worth approximately $32,000. Aventura Private Wealth LLC purchased a new stake in argenex in the 4th quarter worth approximately $38,000. Finally, Sunbelt Securities Inc. acquired a new stake in shares of argenex during the 3rd quarter valued at $36,000. 60.32% of the stock is owned by hedge funds and other institutional investors.

argenex Trading Up 2.4%

argenex stock opened at $822.13 on Friday. The company has a market capitalization of $51.13 billion, a P/E ratio of 36.60, a P/E/G ratio of 1.28 and a beta of 0.46. The firm’s fifty day simple moving average is $759.30 and its 200-day simple moving average is $816.87. argenex SE has a 1-year low of $510.05 and a 1-year high of $934.62.

argenex (NASDAQ:ARGX) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $5.52 earnings per share (EPS) for the quarter. The firm had revenue of $1.31 billion during the quarter. argenex had a net margin of 31.31% and a return on equity of 33.28%. On average, equities research analysts predict that argenex SE will post 25.08 earnings per share for the current year.

Analysts Set New Price Targets

ARGX has been the topic of a number of research reports. Zacks Research raised shares of argenex from a “strong sell” rating to a “hold” rating in a research note on Friday, February 20th. Oppenheimer reduced their price objective on argenex from $1,060.00 to $1,014.00 and set an “outperform” rating for the company in a research report on Thursday, April 2nd. Royal Bank Of Canada lowered their target price on argenex from $925.00 to $890.00 and set an “outperform” rating on the stock in a research note on Friday, February 27th. Citizens Jmp upped their target price on argenex from $925.00 to $944.00 and gave the stock a “market outperform” rating in a research report on Friday, February 27th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of argenex in a research note on Monday, April 20th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $1,017.78.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.